Hot Features
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also dev... Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.59 | -7.47782002535 | 7.89 | 8.19 | 7.295 | 488753 | 7.81908982 | CS |
| 4 | -0.92 | -11.1922141119 | 8.22 | 9.58 | 6.665 | 491385 | 7.78846095 | CS |
| 12 | 0.25 | 3.54609929078 | 7.05 | 9.58 | 6.36 | 452314 | 7.81116716 | CS |
| 26 | 0.46 | 6.72514619883 | 6.84 | 9.58 | 6.015 | 483567 | 7.49819816 | CS |
| 52 | -4.93 | -40.3107113655 | 12.23 | 24.17 | 5.85 | 697983 | 11.6728294 | CS |
| 156 | -19.36 | -72.6181545386 | 26.66 | 45 | 5.85 | 528290 | 18.77699493 | CS |
| 260 | -23.65 | -76.4135702746 | 30.95 | 64.9735 | 5.85 | 550958 | 23.03537718 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.